An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer
This multi-center, prospective observational study will evaluate the treatment patterns, and
the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible
patients will have an initial metastatic breast cancer diagnosis that has not been
previously treated with systemic therapy; patients may be enrolled up to 6 months after the
diagnosis. Data will be collected for up to 8 years.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.